Are We Hitting the Mark With PD-L1 Biomarker Tests?

Denver—Potential hyperprogression and decreased survival in some patients taking checkpoint inhibitors, combined with adverse events and the tremendous financial burden of these agents, make the appropriate use of biomarkers a critical factor when choosing the best population to receive these breakthrough therapies.

In a session during the 2018 annual meeting of the Hematology/Oncology Pharmacy Association, experts emphasized the importance of accurate diagnostic tests measuring